

News, current issues

News Judit Bidló: The Financing of Pharmaceutical Care is Inadequate >>

News How Much Does it Cost to Develop a Drug? >>

News Chronic Disease Management: Here is the Medical Professional Program >>

Macro approach to financing healthcare and medicinal products


Balance of the Health Insurance Fund (HUF), April 2025

Standard	7 758 M	0,1%	
Indication based	16 127 M	6,1%	■
Indication b. 100%	21 412 M	4,0%	■
NPP	4 547 M	0,3%	
Pharmacy	49 845 M	3,7%	■
High value	19 555 M	-14,8%	■
Total	69 400 M	-2,3%	■

Source: Healthware analysis based on NHIFA data


Dynamics of the sales/circulation of prescription-only-medicine

Pharmacy DOT turnover




Source: Healthware analysis based on NHIFA data

Changes to subsidized medicinal product categories, April 2025




Source: Healthware analysis based on NHIFA data

Decision-making index, April 2025



Methodology

Average number of medical sales reps



Share of doctors and others


Source: NHIFA data, Healthware analysis

Deviation from the target

-3,89M HUF
190 744M HUF
51 776M HUF
outturn (expenditure)
outturn (revenue)

Source: Healthware analysis based on NHIFA data

Pharmacy reimbursement turnover



Source: Healthware analysis based on NHIFA data

* The value of social welfare prescriptions is shown under the relevant title

Product offering

Legislation follow up

In the recent years Hungarian pharmaceutical market is characterized by rapidly changing and growing number of regulation instruments, as well as constant system transformations. Healthware Regulatory Compliance is a service in order to support companies with up-to date and comprehensive information in this complex legal environment.


In the framework of regulatory compliance service, immediate alerts December be sent in the form of e-mails about the relevant legal changes along with

a report in order to compare the previous state with the amended one and an interpretation, in an intelligible form.

More about the services: [link](#)


Toplists of reimbursement and number of patients, April 2025

TOP 10 ATCs by all reimbursement paid



Source: Pharmacy turnover data, Healthware analysis


TOP 10 distributors by all reimbursement paid



Source: Pharmacy turnover data, Healthware analysis


Substitutable products, April 2025

Within product deletions, marketing authorization (MAH) erasures were distinguished. We also examined the active substances and brands affected in the procedure. These were divided into two groups according to whether the brand or active substance was completely removed from the formulary or whether there remained (affected) at least one product that belonged to the active substance or brand.



Source: Pharmacy turnover data, Healthware analysis

Product shortage – Turnover data for preparations without equivalent* substitute**




*Equivalent substitutes established by the National Centre for Public Health and Pharmacy

**Turnover in the 12 months preceding the product shortage


Source: Pharmacy turnover data, Healthware analysis

TOP 10 DOT by all reimbursement paid



Source: Pharmacy turnover data, Healthware analysis

TOP 10 patient turnover by all reimbursement paid




Szolgáltató: Bing
© Microsoft, TomTom

Source: Pharmacy turnover data, Healthware analysis

Product shortages

The graph shows the distribution of the reimbursed product shortage list. 531 products had been on the list before April 2025, compared to 53 new product added to the list in the month under review. The newly listed products were grouped according to the number of reimbursed substitutes. Based on this criterion, 4 groups were formed: products with 3 or more, exactly 2, exactly 1 and 0 reimbursed substitutes.



Source: Pharmacy turnover data, Healthware analysis

Highest growth, April 2025 vs March 2025 in HUF

Ranking	Brand	Reimbursement increment	%*
1	 OZEMPIC	381 949 278 HUF	110%
2	 OCREVUS	130 591 606 HUF	132%
3	 Bristol Myers Squibb ELIQUIS	78 132 995 HUF	105%
4	 MERCK MAVENCLAD	75 363 814 HUF	115%
5	 RICHTER GEDEON TANYDON	64 545 158 HUF	114%
6	 NOVARTIS JAKAVI	62 315 767 HUF	105%
7	 janssen ERLEADA	59 290 637 HUF	130%
8	 janssen RYBELSUS	54 943 940 HUF	114%
9	 ewo pharma URSOFALK	50 999 610 HUF	174%
10	 sanofi CLEXANE	47 798 095 HUF	102%

*Compared to the average of the 6 months preceding the reference month
Source: Pharmacy turnover data, Healthware analysis